American Diabetes Association

Table 3 —

Outcome measures of 238 unique type 2 diabetic patients at high risk (76% of 314 patients with postintervention data)

	n^*	Baseline	Mean change	P
HbA_1c
Experimental	63	9.2 ± 0.17	−1.1 ± 0.2	0.0001
Control	75	9.2 ± 0.14	−0.5 ± 0.2	0.006
Systolic blood pressure (mmHg)
Experimental	62	163 ± 2.3	−18.5 ± 3.5	0.0001
Control	54	162 ± 2.5	−17.2 ± 2.9	0.0001
Diastolic blood pressure (mmHg)
Experimental	24	96. ± 1.6	−15 ± 2.9	0.0001
Control	24	95 ± 1.5	−17.7 ± 3.7	0.0001
Cholesterol (mmol/l)
Experimental	33	7.23 ± 0.17	−0.90 ± 0.23	0.0003
Control	30	7.25 ± 0.25	−0.75 ± 0.25	0.004

	n^*	Baseline	Mean change	P
HbA_1c
Experimental	63	9.2 ± 0.17	−1.1 ± 0.2	0.0001
Control	75	9.2 ± 0.14	−0.5 ± 0.2	0.006
Systolic blood pressure (mmHg)
Experimental	62	163 ± 2.3	−18.5 ± 3.5	0.0001
Control	54	162 ± 2.5	−17.2 ± 2.9	0.0001
Diastolic blood pressure (mmHg)
Experimental	24	96. ± 1.6	−15 ± 2.9	0.0001
Control	24	95 ± 1.5	−17.7 ± 3.7	0.0001
Cholesterol (mmol/l)
Experimental	33	7.23 ± 0.17	−0.90 ± 0.23	0.0003
Control	30	7.25 ± 0.25	−0.75 ± 0.25	0.004

Data are means ± SEM.

The sum of this column (365) is greater than the number of unique patients with high risk factors (238) because many patients had more than one risk factor.

View Large

This Feature Is Available To Subscribers Only